AVI BioPharma.

‘That is an important day for family members fighting muscular dystrophy,’ said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors. ‘AVI BioPharma already completed a 19-patient medical trial in britain confirming the potential of eteplirsen to be a effective and safe disease-modifying drug for DMD . Jerry Mendell receives funding from MDA to help initiate this randomized, double-blind, placebo-controlled 12-patient trial had a need to further test safety, efficacy and optimum dosing.’ ‘Twenty-five years ago, MDA-funded investigators recognized the dystrophin gene that, when mutated causes Duchenne muscular dystrophy and also the somewhat milder Becker muscular dystrophy ,’ explained Mendell, Curran-Peters Seat of Pediatric Analysis at Nationwide Children’s Medical center, and Professor of Neurology and Pediatrics at Ohio State University.Even though methods described here do not stand for a widely implementable vaccine strategy, the induction of sterile protection against a homologous malaria challenge shows that the concept of a whole-parasite malaria vaccine warrants further consideration. In addition, this model allows the nature of protecting immune responses against malaria, both antigen-specific and stage-specific, to be further investigated.. Algae may the key to SARS vaccine A protein from algae may have what it takes to avoid Serious Acute Respiratory Syndrome infections, according to fresh research. A recently available study has discovered that mice treated with the protein, Griffithsin , had a completely survival rate after exposure to the SARS coronavirus , when compared with a thirty % survival for untreated mice.